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CYP 2D6*4 polymorphism and interindividual response variation to metoprolol in
stage 1 hypertensive patients: no association in a rural Indian population?
1,2

2,3,

2,4

Rajagopal AYYAPPADHAS , Unnikrishnan DHANALEKSHMI *, Chelliah JESTIN
1
AIMST University, Kuala Lumpur, Malaysia
2
Institute of Pharmacology, Madras Medical College, Chennai, India
3
Natural Products Chemistry Division- Pharmacology Unit, CSIR-North East Institute of Science and Technology, Assam, India
4
International Medical University, Kuala Lumpur, Malaysia
Received: 29.07.2013

Accepted: 10.05.2014

Published Online: 01.04.2015

Printed: 30.04.2015

Background/aim: Genetic polymorphism of CYP2D6 shows diverse pharmacokinetic and pharmacodynamic variation. Therefore, the
present work was designed to study the variation in therapeutic responses to metoprolol (MP) in stage 1 hypertensive patients and also
aims to verify the association of CYP2D6*4 polymorphism and response variation in an Indian population for the first time.
Materials and methods: Clinically, a total of 119 hypertensive patients and 116 healthy individuals as controls were included. Patients
were treated with MP extended release 25 mg tablets once daily for 2 weeks. Reduction in systolic blood pressure, diastolic blood
pressure, and pulse rate were recorded before and after the treatment. For genotyping, genotypes of 89 hypertensive patients and 71
healthy controls were investigated for CYP2D6*4 polymorphism.
Results: Based on reduction in systolic blood pressure, 26% of the patients did not respond to the MP treatment. Of the patients that
responded, 28% responded very slowly, 35% (19 males, 23 females) responded moderately, and 12% (8 males, 6 females) showed a
good response to MP. For genotype analysis, we pooled 89 hypertensive patients and 71 controls. No association was found between
CYP2D6*4 polymorphism and MP response.
Conclusion: We found no relationship between MP response and CYP2D6*4 genotype in an Indian population in our study.
Key words: Metoprolol, CYP2D6*4, polymorphism, hypertension

1. Introduction
Hypertension is one of the leading causes of cardiovascular
morbidity and mortality. Worldwide, it accounts for
more than 5% of total deaths (1). This disorder is directly
associated with stroke, heart disease, renal failure, and
vascular diseases (2). In India, about one-fifth of urban
adults (≥20 years old) were reported to be hypertensive.
The prevalence of hypertension in India was found to
be lower in rural populations (10%) compared to urban
populations (25%) (3). Management of hypertension
includes administration of antihypertensive drugs such
as angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers, beta-blockers, diuretics,
Ca2+ channel blockers, and peripheral vasodilators (4).
Beta-blockers are efficient in reducing the complications
of hypertension (1). Metoprolol (beta-blocker) is a
cardioselective beta-1 adrenergic receptor antagonist
primarily metabolized by CYP2D6. CYP2D6 is located
on the human chromosome 22q13.1 (5). It is a member
* Correspondence: dhanamum@yahoo.co.in
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of the cytochrome P450 family with a mixed function
oxidase activity that oxidizes/metabolizes xenobiotics and
other compounds (6). CYP2D6 is highly polymorphic,
with 80 different alleles and allelic variants identified
(7,8). Genetic variation of CYP2D6 has great clinical
significance in the metabolism of beta-adrenergic blocking
agents, antiarrhythmics, psycholeptics, antidepressants,
and narcotic analgesics (9). A linear relationship was also
observed between the variants of the CYP2D6 gene and
the metabolic clearance of metoprolol (10). Individuals
with CYP2D6 gene variants are classified functionally into
3 different phenotypes, based on their ability to metabolize
drugs: ultrarapid, extensive, and poor metabolizers, with
low, normal, and high plasma concentrations of the drug,
respectively. Furthermore, increased plasma metoprolol
concentration was observed in poor metabolizers (11).
Variation in the pharmacokinetics and pharmacodynamics
of metoprolol was observed in women as compared
with men (12). Women had significantly higher plasma
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metoprolol concentrations than men, independent of
CYP2D6 genotype (13). Metoprolol is a beta-blocker
and about 70%–80% of the drug is metabolized by the
cytochrome P450 2D6 enzyme (CYP2D6). The present
study evaluated the interindividual response variation to
metoprolol therapy in stage 1 hypertension along with
other factors such as age and sex. Despite the vast ethnic
variation of the Indian population, no pharmacogenomic
study has been carried out on metoprolol in this population.
The main aim of the study was to evaluate the association
of CYP2D6*4 polymorphism with the therapeutic efficacy
of metoprolol as influenced by age, sex, and body mass
index (BMI).
2. Materials and methods
2.1. Subjects
The institutional human ethics committee approved the
study (1299/PD/Ethics/Dean/GCH/Chennai) and the
study was conducted according to good clinical practice
guidelines. Newly diagnosed hypertensive patients
without antihypertensive drug therapy were considered as
the subject group. All the patients included in the study
were attending the hypertensive clinic at the Government
General Hospital, Madras Medical College, Chennai.
Normotensive individuals attending the general medical
outpatient unit were considered as the controls. The
inclusion criteria for the study group were ambulatory
patients of either sex, aged 30–65, with systolic blood
pressure ranging from 140 to 160 mmHg and diastolic
blood pressure ranging from 90 to 100 mmHg. The control
group consisted of 116 healthy individuals matched to age
and sex with the study subjects, with systolic blood pressure
ranging from 90 to 130 mmHg and diastolic blood pressure
ranging from 60 to 85 mmHg without clinically significant
renal, hepatic, gastroenterology, or metabolic disorders.
The exclusion criteria included a history of bronchospasm
or asthma, thyrotoxicosis and peripheral vascular
diseases, diabetes mellitus, pregnancy or breastfeeding,
sitting diastolic blood pressure greater than 110 mmHg,
malignant hypertension, secondary hypertension, cardiac
surgery and other cardiac intervention or stroke in the past
3 months, congestive heart failure, and clinically significant
hepatic, renal, neurological, gastrointestinal, metabolic,
hematological, or psychiatric problems. In addition to
the above, the following patients were also excluded:
patients under treatment with Ca2+ channel blockers, ACE
inhibitors and digoxin, lithium, catecholamine-depleting
drugs (reserpine, MOA inhibitors), quinidine, methadone,
fluoxetine, fluvoxamine, paroxetine, sertraline, or
propafenone; known smokers and alcoholics; and those
with known hypersensitivity to metoprolol or betablockers. Moreover, patients with SGOT/SGPT values of
>1.5 times the upper limit of the normal range (10–40

unit/mL), alkaline phosphatase (13–39 IU/L) or total
serum bilirubin of >1.2 times the upper limit of normal, or
creatinine of >1.2 mg/dL were excluded. Informed consent
was obtained from the patients and the control group after
explaining the purpose of study.
Based on the inclusion criteria, 166 patients were
selected out of 525 hypertensive patients screened. A
metoprolol extended release tablet (25 mg/day) was
administered orally to 166 patients for 2 weeks. One
hundred and nineteen hypertensive patients (51 males
and 68 females) completed the study, as the remaining 47
patients failed to turn up. Blood samples were collected
from 119 patients and subjected for DNA extraction. DNA
extraction was completed successfully for 89 samples and
they were analyzed for genotypic variation; the remaining
30 samples were not successful. Blood samples were
collected from 116 healthy individuals, of which 71 were
subjected to genotypic analysis; the remaining samples
were not successful during DNA extraction.
2.2. Clinical investigations
Detailed medical history, physical examination, and
baseline laboratory investigations were documented.
Sitting blood pressure, pulse rate, respiratory rate, and body
temperature were measured before and after medication.
ECG and chest X-rays were taken to rule out cardiac and
respiratory complications. In both patient and control
groups, the following tests were conducted: renal function
test (sugar, urea, and creatinine), liver function test (SGOT,
SGPT, and bilirubin), lipid profiles (total cholesterol, HDL,
and triglycerides), and serum electrolytes.
2.3. Genomic DNA extraction and analysis
The genotypes of 89 hypertensive patients and 71
controls were analyzed for CYP2D6*4. Five milliliters
of venous blood was collected from the subject and
control groups. Genomic DNA was extracted from
peripheral blood cells and dissolved in 1X TE buffer or
Milli-Q water and quantified spectrophotometrically.
Genotyping was carried out using the PCR-RFLP
method. CYP2D6*4 (355 bp) was detected by PCR
amplification using GCCTTCGCCAACCACTCCG and
AAATCCTGCTCTTCCGAGGC as the forward and
reverse primers, respectively. PCR was performed in a 10µL volume containing 50–100 ng of DNA, 5 pmol of each
primer, 10 mM dNTPs, 10X PCR reaction mixture, 50 mM
MgCl2, and 0.25 U of Taq polymerase. Following initial
denaturation for 5 min at 94 °C, PCR was performed for
35 cycles of denaturation for 45 s at 94 °C, annealing for 30
s at 59 °C, and an extension for 30 s at 72 °C, and further
extended for 3 min at 72 °C. Amplification was checked on
2% agarose gel. The amplified PCR product was digested
with MvaI (37 °C) and the digested PCR products were
separated by 3% agarose gel electrophoresis. The restriction
site was generated by a substitution of G→A at nucleotide
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position 1934 (7). The RFLP assay distinguished the wild
type allele (250 bp and 105 bp) from the mutant allele (355
bp).
2.4 Statistical analysis
The data generated from the study were analyzed by
ANOVA and multiple regression analysis with SPSS.
CYP2D6*4 allele frequency and odds ratio were calculated
by chi-square test.
3. Results
The mean age, BMI, cholesterol level, systolic and diastolic
blood pressure, and reduction of systolic and diastolic
blood pressure in males and females on metoprolol
treatment are represented in Tables 1 and 2. As observed
in control subjects, females had significantly higher BMIs
than males. A significant age difference was found in BMI
and diastolic blood pressure.
The hypertensive patients were classified into 4
different groups (nonresponders, very slow, moderate, and

good responders) based on the reduction in systolic blood
pressure and diastolic blood pressure following metoprolol
treatment as represented in Tables 3 and 4, respectively.
About 26% of the patients did not respond to metoprolol
treatment. Of the patients that responded, 27% responded
very slowly, 35% responded moderately, and 12% of the
patients showed a good response to metoprolol.
Gene frequencies of CYP2D6*4 for the patients and
control subjects are given in Table 5. The frequency of
the ‘+’ allele was about 15.5% in control subjects and
about 20.8% in hypertensive patients. Odds ratios for the
association of the CYP2D6*4 allele with the responders
and nonresponders to metoprolol treatment are given in
Table 6. Nonresponders are those patients whose blood
pressure did not reduce or reduced by less than 4 mmHg
following an administration of 25 mg/day metoprolol
for 15 days. Responders are those patients whose blood
pressure reduced by ≥4 mmHg. The RFLP assay results are
depicted in the Figure.

Table 1. Mean age, BMI, and cholesterol level of hypertensive patients.
Parameter

Males

Females

N

51

68

Age (years)

49 ± 9.2

50.8 ± 9.7

BMI (kg/m )

25.7 ± 3.5

27.7 ± 4.2

Cholesterol (mg/dL)

185.2 ± 32.1

179.4 ± 44.4

2

BMI: Body mass index. Values are expressed as mean ± standard deviation.
Table 2. Influence of metoprolol on SBP, DBP, and HR in hypertension patients.
Parameters

Males BT

Males AT

Difference

Females BT

Females AT

Difference

SBP (mmHg)

148.3 ± 8.3

135.4 ± 15

12.8 ± 11.8

149.3 ± 8.5

137.7 ± 10.3

11.8 ± 9.7

DBP (mmHg)

95.5 ± 4.7

87.4 ± 8.7

8.3 ± 7.5

95.1 ± 4.8

88.0 ± 8.6

6.9 ± 7.4

HR(Pulse/min)

83.6 ± 7.2

78.0 ± 8.0

5.4 ± 6.5

84.8 ± 8.9

80.4 ± 7.7

4.5 ± 7.8

SBP: Systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; BT: before treatment; AT: after treatment. Values are
expressed as mean ± standard deviation.
Table 3. Classification of hypertensive patients based on the reduction in systolic blood pressure after metoprolol treatment.
Variants
Males
Females
Total

Nonresponders
n

13

Responders
Very slow responders

Moderate responders

Good responders

11

19

8

%
n

Total
51
42.86

18

21

23

6

68

%

57.14

n

119

Nonresponders: ≤4 mmHg; very slow responders: >4 and ≤10 mmHg; moderate responders: >10 and ≤20 mmHg; good responders:
>20 mmHg.
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Table 4. Classification of hypertensive patients based on the reduction in diastolic blood pressure after metoprolol treatment.

Variants
n

Males

14

Responders
Very slow responders

Moderate responders

Good responders

25

11

1

Total
51

%

Females
Total

Nonresponders

n

42.86
25

28

15

0

68

%

57.14

n

119

Nonresponders: ≤4 mmHg; very slow responders: >4 and ≤10 mmHg; moderate responders: >10 and ≤20 mmHg; good responders:
>20 mmHg.
Table 5. Gene frequency of CYP2D6*4 allele among responders, nonresponders, and controls.
Groups

AA

GA

GG

P (± SE)

Responders (N = 65)

2 (3.1%)

20 (30.8%)

43 (66.2%)

0.185 (0.018)

Nonresponders (N = 24)

1 (4.2%)

11 (45.8%)

12 (50%)

0.479 (0.051)

Controls (N = 71)

1 (1.4%)

20 (28.2%)

50 (70.4%)

0.1549 (0.016)

N: Sample size. P < 0.05 is significant; SE: standard error. AA, GA, GG: genotypes. Nonresponders are those patients
whose blood pressure did not reduce or reduced by 4 mmHg or less following administration of 25 mg/day metoprolol
for 15 days. Responders are those patients whose blood pressure reduced by ≥4 mmHg.
Table 6. Odds ratio of CYP2D6*4 allele with the hypertensive patients, controls, responders, and nonresponders.
Groups

Chi-square

P-value

Odds ratio

95% CI

HT patients vs. controls (N = 89)

1.472

0.225

1.431

0.804

2.546

Nonresponders vs. controls (N = 24)

3.207

0.073

2.026

0.937

4.390

Responders vs. controls (N = 65)

0.426

0.514

1.235

0.659

2.316

N: Sample size. CI: Confidence interval, P < 0.05 is significant. Nonresponders are those patients whose blood pressure did not reduce or
reduced by 4 mmHg or less following administration of 25 mg/day metoprolol for 15 days. Responders are those patients whose blood
pressure reduced by ≥4 mmHg.

4. Discussion
Metoprolol
has
large
pharmacokinetic
and
pharmacodynamic variation due to the inherited
variations in the drug-metabolizing enzyme (CYP2D6)
and adrenergic beta-1 receptor polymorphism (14).
Even though there is large ethnic variation in the Indian
population, to date limited pharmacogenetic data are
available for metoprolol. This pilot study aimed to discover
the variation in response to metoprolol therapy in stage 1
hypertension.
Large interpatient variability in therapeutic response to
drugs, including cardiovascular drugs, has been reported

by many scientists (15). In a study by the US Veterans
Administration, there were substantial variations in blood
pressure responses to antihypertensive therapy, but to date
there is no accurate means of identifying the individuals
who respond quite well to drugs (14,16).
In the case of males, individuals in the 40–45 age
group and the 55–60 age group were slow responders.
Individuals in the 35–40 age group were good responders.
In the case of females, individuals in the 35–40 and 45–
50 age groups were poor responders compared to other
age groups. A gradual increase in response was observed
above 45 years. The frequencies of the CYP2D6*4 allele
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Lane 1

2

3

4

355bp
250bp

105bp

5

6

7

8

1000bp
900bp
800bp
700bp
600bp
500bp
400bp
300bp
200bp
100bp

Figure. Agarose gel electrophoresis (1.5%), CYP2D6*4 allele primer digested
with MvaI restriction enzyme. Lanes 1 and 5, 250 and 105 bp; lane 3, 355, 250,
and 105 bp; and lane 8, 1000 bp ladder.

in control subjects and hypertensive patients were 15.5%
and 20.8%, respectively. The CYP2D6*4 allele was not
associated with hypertension (P = 0.23). No association
was found between the presence of CYP2D6*4 allele and
nonresponders to metoprolol. Responders to metoprolol
also showed no significant association with the CYP2D6*4
allele.
The study by Fredman et al. had 22% nonresponders
to metoprolol (17). Similarly, in our study, we observed
that one-fourth of the study population did not respond to
metoprolol. Females were more likely to be nonresponders
than males. Males within the 35–40 age group were good
responders to metoprolol; females aged 30–35 and 40–45
also responded well. No sex difference was observed in
blood pressure, pulse rate, or cholesterol level for patients.
Among nonresponders, the ‘+’ allele frequency was over
2 times higher than that observed in the overall sample
of hypertensive patients and over 3 times higher than the
value observed in control subjects.
Among the 3 genotypes, frequency of the AA genotype
is very small (usually <5%) in comparison with the other
2 genotypes. Since the AA genotype frequency and sample
size were very small, the odds ratios were calculated using
allele frequencies instead of genotype frequencies. The

356

result of this analysis was compared with various subject
samples of hypertensive patients. In all 3 correlations (all
hypertensive patients, nonresponders, and responders),
the odds ratios were positive or above 1. However, none of
them were statistically significant (P < 0.05).
In conclusion, one-fourth of the study patients were
nonresponders to metoprolol. Males aged from 30 to 35
years and females aged from 40 to 45 years were good
responders. However, we found no relationship between
metoprolol response and CYP2D6*4 genotype. This study
must be further continued in larger populations to explore
other genetic factors to confirm this finding.
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